All In Biotech

Drug Trial Radar · NCT05905328

Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy

Phase 1B/2A Study of CTO1681 for the Prevention and Treatment of Cytokine Release Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Dec 28, 2023

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
CytoAgents, Inc.Industry
Sponsor type
Industry
Collaborators
National Cancer Institute (NCI)
First posted
Jun 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS). This study will enroll adult patients with lymphoma or multiple myeloma who are scheduled to receive CAR T-cell therapy. The first phase of the study is open label with dose escalation. Participants will start taking CTO1681 either the day before starting lymphodepleting chemotherapy or just prior to receiving their CAR T-cell therapy, depending on their cohort assignment. In both cases participants will continue to take the study drug three times daily until 13 days after their CAR T-cell infusion.

Conditions

  • Cytokine Release Syndrome

Interventions

  • CTO1681 10 µgDrug

    Administered 3 times daily for 15 days (initial cohort).

  • CTO1681 20 μgDrug

    Administered 3 times daily for 15 days (successive cohort).

  • CTO1681 30 μgDrug

    Administered 3 times daily for 15 days (successive cohort).

  • CTO1681 10 µg Run-in / 20 µg TreatmentDrug

    Administered 3 times daily for up to 21 days (successive cohort).

  • CTO1681 20 µg Run-in / 30 µg TreatmentDrug

    Administered three times daily for up to 21 days (successive cohort).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: 6 months following start of treatment

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Irvine - Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.